Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer-Reference-Cited by-同舟云学术

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

Published:2017-04-28 Issue:14 Volume:77 Page:3834-3845
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Li Bo,Ni Chonghaile Triona,Fan Yue,Madden Stephen F.,Klinger Rut,O'Connor Aisling E.,Walsh Louise,O'Hurley Gillian,Mallya Udupi Girish,Joseph Jesuchristopher,Tarrant Finbarr,Conroy Emer,Gaber Alexander,Chin Suet-Feung,Bardwell Helen A.,Provenzano Elena,Crown John,Dubois Thierry,Linn Sabine,Jirstrom Karin,Caldas Carlos,O'Connor Darran P.,Gallagher William M.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7;European Journal of Medicinal Chemistry;2024-01

2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis‐generating study;Clinical and Translational Medicine;2023-11-30

3. Association Between High Expression of Phosphorylated-STMN1 and Mesenchymal Marker Expression and Cancer Stemness in Breast Cancer;Anticancer Research;2023-11-29

4. Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment;Molecules;2023-11-09

5. N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer;European Journal of Pharmacology;2023-09